Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : ???????Eckert & Ziegler with Strong First Half of 2021

08/12/2021 | 01:46am EDT

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results/Half Year Report
???????Eckert & Ziegler with Strong First Half of 2021

12.08.2021 / 07:45
The issuer is solely responsible for the content of this announcement.


Berlin, 12 August 2021. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a new record result in the first half of 2021 with a net profit of ? 22.3 million or ? 1.08 per share. Revenues of the Group amounted to ? 89.5 million and were thus 7% above the previous year's level.

Although a large part of this growth is due to income from the sale of the tumor irradiation business, the development of the operating business in both segments is also extremely encouraging. The analysis of the operating result, which rose from ? 19.0 million in the previous year to ? 29.4 million, clearly illustrates this. Approximately half of the increase of ? 10.4 million compared with the first half of 2020 (? 5.4 million) results from the increase in the balance of other operating income and expenses, while a further ? 5.0 million is attributable to improvements in the operating result.

Despite the deconsolidation of the tumor irradiation business and the associated loss of this revenue, the Medical segment was able to increase its sales revenues by a total of ? 3.2 million or 8% to ? 41.5 million. The main growth driver continued to be the Radiopharmaceuticals business, which includes pharmaceutical radioisotopes, plant engineering, and project business. Sales revenues from laboratory equipment also increased.

At ? 50.3 million, the Isotope Products segment achieved sales revenues that were ? 3.2 million or around 7% higher than in the first six months of 2020. Following the slumps in connection with the Covid and oil crises last year, the segment was thus able to grow again as expected.

With around ? 22 million, the Eckert & Ziegler Group achieved earnings in the first half of 2021 that exceeded original expectations. The Executive Board therefore expects the Group result to exceed the forecast for net income in fiscal year 2021 published at the beginning of the year by around 20%. As already published in the ad-hoc announcement of July 27, 2021, the Executive Board is therefore increasing the target for net income from ? 29 million to ? 35 million, which corresponds to an EPS of around ? 1.70.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz221e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1225830

 
End of News DGAP News Service

1225830  12.08.2021 

fncls.ssp?fn=show_t_gif&application_id=1225830&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
10/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : & Ziegler Acquires 53,000 Square Feet Facility for ..
PU
10/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : & Ziegler Acquires 53,000 Square Feet Facility for ..
EQ
10/11PRESS RELEASE : Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Con..
DJ
09/30Eckert & Ziegler Strahlen- und Medizintechnik AG english
DJ
09/28ECKERT & ZIEGLER : Hauck & Aufhauser reaffirms its Buy rating
MD
09/28ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
09/27ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Nantes University Hospital Doses First Patients wit..
PU
09/27ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Nantes University Hospital Doses First Patients wit..
EQ
09/27PRESS RELEASE : Nantes University Hospital Doses First Patients with Eckert & Ziegler's No..
DJ
09/23ECKERT & ZIEGLER STRAHLEN- UND MEDIZ : Release according to Article 40, Section 1 of the W..
DJ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2021 180 M 208 M 208 M
Net income 2021 26,9 M 31,2 M 31,2 M
Net cash 2021 96,9 M 112 M 112 M
P/E ratio 2021 97,3x
Yield 2021 0,35%
Capitalization 2 645 M 3 072 M 3 068 M
EV / Sales 2021 14,2x
EV / Sales 2022 11,2x
Nbr of Employees 814
Free-Float 67,0%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 127,50 €
Average target price 172,00 €
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar L÷ffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG184.34%3 072
JOHNSON & JOHNSON4.26%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY45.14%220 979